JP2003532369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003532369A5 JP2003532369A5 JP2000566424A JP2000566424A JP2003532369A5 JP 2003532369 A5 JP2003532369 A5 JP 2003532369A5 JP 2000566424 A JP2000566424 A JP 2000566424A JP 2000566424 A JP2000566424 A JP 2000566424A JP 2003532369 A5 JP2003532369 A5 JP 2003532369A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- seq
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 27
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- 125000003275 alpha amino acid group Chemical group 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Description
【特許請求の範囲】
【請求項１】 （ａ）配列番号１に示したアミノ酸配列と、
（ｂ）配列番号１に示したアミノ酸配列の対立遺伝子変異体のアミノ酸配列と、
（ｃ）配列番号１に示したアミノ酸配列の配列変異体のアミノ酸配列であって、該配列変異体は、ストリンジェントな条件下で、配列番号２に示した核酸分子にハイブリダイゼーションする核酸分子によりコードされることを特徴とするアミノ酸配列と、
（ｄ）配列番号１に示した、アミノ酸約６番目からアミノ酸約３５９番目までの成熟受容体ポリペプチドのアミノ酸配列と、
（ｅ）アミノ酸約１番目からアミノ酸約２３番目までの、配列番号１に示したポリペプチドのアミノ酸配列と、
（ｆ）ポリペプチド（ａ）〜（ｅ）のいずれか１つのエピトープ含有領域のアミノ酸配列と
からなる群から選択されるアミノ酸配列を有する単離ポリペプチド。
【請求項２】 請求項１のポリペプチドの（ａ）〜（ｆ）に選択的に結合する単離抗体。
【請求項３】 （ａ）配列番号２に示したヌクレオチド配列と、
（ｂ）配列番号１に示したアミノ酸配列をコードするヌクレオチド配列と、
（ｃ）（ａ）または（ｂ）のヌクレオチド配列のいずれかに相補的なヌクレオチド配列と
からなる群から選択されるヌクレオチド配列を有する単離核酸分子。
【請求項４】 （ａ）ストリンジェントな条件下で、配列番号２に示したヌクレオチド配列にハイブリダイゼーションする、配列番号１に示したアミノ酸配列の配列変異体のアミノ酸配列をコードするヌクレオチド配列と、
（ｂ）（ａ）のヌクレオチド配列に相補的なヌクレオチド配列と
からなる群から選択されるヌクレオチド配列を有する単離核酸分子。
【請求項５】 （ａ）配列番号１に示したアミノ酸１０７〜３５９番目のアミノ酸配列の断片をコードするヌクレオチド配列であって、該断片は、少なくとも７個の連続したアミノ酸を含むことを特徴とするヌクレオチド配列と、
（ｂ）（ａ）のヌクレオチド配列に相補的なヌクレオチド配列と
からなる群から選択されるヌクレオチド配列を有する単離核酸分子。
【請求項６】 請求項３〜５のいずれかの核酸配列を含む核酸ベクター。
【請求項７】 請求項６のベクターを含む宿主細胞。
【請求項８】 （ａ）〜（ｆ）のポリペプチド配列のいずれかをコードするヌクレオチド配列を宿主細胞に導入するステップと、タンパク質が核酸から発現される条件下で宿主細胞を培養するステップとを含む請求項１のポリペプチドのいずれかを製造する方法。
【請求項９】 サンプル中の請求項１のポリペプチドのいずれかの存在を検出する方法であって、前記サンプルを、サンプル中のポリペプチドの存在を特異的に検出できる物質と接触させるステップと、次いでポリペプチドの存在を検出するステップとを含む方法。
【請求項１０】 上記物質は、上記ポリペプチドとの選択的な物理的結合が可能である請求項９の方法。
【請求項１１】 上記物質は、上記ポリペプチドに結合する請求項１０の方法。
【請求項１２】 上記物質は、抗体である請求項１１の方法。
【請求項１３】 上記物質は、リガンドである請求項１１の方法。
【請求項１４】 請求項９の方法に使用される試薬を含むキットであって、前記試薬は、上記ポリペプチドに特異的に結合する物質を含むことを特徴とするキット。
【請求項１５】 サンプル中の請求項３〜５のいずれかの核酸配列のいずれかの存在を検出する方法であって、サンプルを、ストリンジェントな条件下で核酸配列とハイブリダイゼーションするオリゴヌクレオチドと接触させるステップと、オリゴヌクレオチドがサンプル中の核酸配列に結合するかどうかを決定するステップとを含む方法。
【請求項１６】 存在を検出する核酸は、ｍＲＮＡである請求項１５の方法。
【請求項１７】 請求項１５の方法に使用する試薬を含むキットであって、前記試薬は、ストリンジェントな条件下で核酸分子のいずれかにハイブリダイゼーションする化合物を含むキット。
【請求項１８】 請求項１のポリペプチドのいずれかに結合する物質を同定する方法であって、ポリペプチドを、前記ポリペプチドに結合する物質と接触させるステップと、前記ポリペプチドに結合した物質により形成された複合体をアッセイするステップとを含む方法。
【請求項１９】 請求項１のいずれかのポリペプチドの活性を調節する方法であって、請求項１のポリペプチドのいずれかを、物質がポリペプチドの活性を調節できる条件下で、前記物質と接触させることを含む方法。
【請求項２０】 上記調節は、ＣＤ３４＋骨髄細胞、及びＣＤ４Ｔリンパ球、およびＣＤ８Ｔリンパ球からなる群から選択した組織から得られる細胞で行われる請求項１９の方法。
【請求項２１】 上記リンパ球は、ＣＤ８Ｔ細胞またはＣＤ４Ｔ細胞である請求項２０の方法。
【請求項２２】 上記骨髄細胞は、ＣＤ３４+細胞である請求項２０の方法。
【請求項２３】 上記調節は、ＣＤ８Ｔ細胞、ＣＤ４Ｔ細胞、またはＣＤ３４+骨髄細胞に関する疾患に罹患した患者で行われる請求項１９の方法。
【請求項２４】 上記疾患は、血小板減少症または炎症に関する請求項２３に記載の方法。
[Claims]
(1) an amino acid sequence represented by SEQ ID NO: 1 ;
( B ) an amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO: 1 ,
( C ) an amino acid sequence of a sequence variant of the amino acid sequence set forth in SEQ ID NO: 1, wherein the sequence variant comprises a nucleic acid molecule that hybridizes under stringent conditions to the nucleic acid molecule set forth in SEQ ID NO: 2. An amino acid sequence characterized by being encoded ;
( D ) the amino acid sequence of the mature receptor polypeptide from about amino acid 6 to amino acid 359 shown in SEQ ID NO: 1 ,
( E ) an amino acid sequence of the polypeptide shown in SEQ ID NO: 1 from about amino acid 1 to about amino acid 23 ;
( F ) An isolated polypeptide having an amino acid sequence selected from the group consisting of the amino acid sequence of the epitope-containing region of any one of the polypeptides (a) to ( e ).
2. An isolated antibody which selectively binds to (a) to ( f ) of the polypeptide of claim 1.
(A) a nucleotide sequence represented by SEQ ID NO: 2 ;
( B ) a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1 ,
( C ) an isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of: a nucleotide sequence complementary to any of the nucleotide sequences of (a) or (b) .
(A) a nucleotide sequence encoding an amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO: 1 that hybridizes under stringent conditions to the nucleotide sequence shown in SEQ ID NO: 2 ;
( B ) an isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of: a nucleotide sequence complementary to the nucleotide sequence of (a ) .
5. (a) A nucleotide sequence encoding a fragment of the amino acid sequence of amino acids 107 to 359 shown in SEQ ID NO: 1, wherein said fragment contains at least 7 consecutive amino acids. A nucleotide sequence ,
( B ) an isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of: a nucleotide sequence complementary to the nucleotide sequence of (a ) .
6. A nucleic acid vector comprising the nucleic acid sequence according to claim 3.
7. A host cell comprising the vector of claim 6.
8. A step of introducing a nucleotide sequence encoding any of the polypeptide sequences (a) to ( f ) into a host cell, and culturing the host cell under conditions in which the protein is expressed from the nucleic acid. A method for producing any of the polypeptides of claim 1 comprising:
9. A method for detecting the presence of any of the polypeptides of claim 1 in a sample, the method comprising contacting the sample with a substance capable of specifically detecting the presence of the polypeptide in the sample. And then detecting the presence of the polypeptide.
10. The method of claim 9, wherein said substance is capable of selective physical association with said polypeptide.
11. The method of claim 10, wherein said substance binds to said polypeptide.
12. The method according to claim 11, wherein said substance is an antibody.
13. The method of claim 11, wherein said substance is a ligand.
14. A kit comprising the reagent used in the method of claim 9, wherein the reagent comprises a substance that specifically binds to the polypeptide.
15. A method for detecting the presence of any of the nucleic acid sequences of any one of claims 3 to 5 in a sample, the method comprising: combining the sample with an oligonucleotide that hybridizes under stringent conditions to the nucleic acid sequence. Contacting, and determining whether the oligonucleotide binds to a nucleic acid sequence in the sample.
16. The method according to claim 15, wherein the nucleic acid whose presence is to be detected is mRNA.
17. A kit comprising a reagent for use in the method of claim 15, wherein said reagent comprises a compound that hybridizes under stringent conditions to any of the nucleic acid molecules.
18. A method for identifying a substance that binds to any of the polypeptides of claim 1, comprising contacting the polypeptide with a substance that binds to the polypeptide; and a substance that binds to the polypeptide. Assaying the complex formed by the method.
19. A method for modulating the activity of any of the polypeptides of claim 1, wherein the method comprises the step of treating any of the polypeptides of claim 1 under conditions that allow the substance to modulate the activity of the polypeptide. Contacting with a method.
20. The method of claim 19, wherein said modulation is performed on cells obtained from a tissue selected from the group consisting of CD34 + bone marrow cells and CD4 T lymphocytes and CD8 T lymphocytes.
21. The method of claim 20, wherein said lymphocytes are CD8 T cells or CD4 T cells.
22. The method of claim 20, wherein said bone marrow cells are CD34 + cells.
23. The method of claim 19, wherein said modulation is performed in a patient suffering from a disease involving CD8 T cells, CD4 T cells, or CD34 + bone marrow cells.
24. The method of claim 23, wherein the disease is associated with thrombocytopenia or inflammation.
本発明は、配列番号１に示すアミノ酸配列を有するポリペプチドを含む単離１４４００受容体ポリペプチドを提供する。
The present invention provides an isolated 14400 receptor polypeptide comprising a polypeptide having the amino acid sequence shown in SEQ ID NO: 1.
本発明はまた、配列番号２に示される配列を有する、単離１４４００受容体核酸分子を提供する。
The present invention also has an array of Ru shown in SEQ ID NO: 2 provides isolated 14400 receptor nucleic acid molecule.
本発明はまた、配列番号１に示されるアミノ酸配列と実質的に相同なアミノ酸配列を有する変異体ポリペプチドを提供する。
The present invention also provides a variant polypeptide having an amino acid sequence substantially homologous and indicated luer amino acid sequence in SEQ ID NO: 1.
本発明はまた、配列番号２に示されるヌクレオチド配列と実質的に相同な変異体核酸配列を提供する。
The present invention is also shown in SEQ ID NO: 2 provides Runu Kureochido sequence substantially homologous variant nucleic acid sequences.
したがって、本発明は、図１（配列番号１）に記載の推定アミノ酸配列を有する新規のＧＰＣＲに関する。
Accordingly, the present invention is new about the GPCR of regulations that have a deduced amino acid sequence in FIG. 1 (SEQ ID NO: 1).
「１４４００受容体ポリペプチド」または「１４４００受容体タンパク質」は、配列番号１に記載のポリペプチドをいう。しかし、用語「受容体ポリペプチド」は、本明細書中に記載の多数の変異体ならびに全長１４４００ポリペプチドおよび変異体由来のフラグメントをさらに含む。
"14400 receptor polypeptide" or "14400 receptor protein" refers to a polypeptide de set forth in SEQ ID NO: 1. However, the term “receptor polypeptide” further includes many of the variants described herein as well as
ポリヌクレオチドPolynucleotide
本発明は、１４４００受容体タンパク質をコードする単離されたポリヌクレオチドを提供する。用語「１４４００ポリヌクレオチド」または「１４４００核酸」とは、配列番号２で示された配列をいう。用語「受容体ポリヌクレオチド」または「受容体核酸」は、さらに、１４４００ポリヌクレオチドの変異体および断片を含む。
The present invention provides an isolated polynucleotide encoding a 14400 receptor protein. The term "14400 polynucleotide" or "14400 nucleic acid" refers to a sequence that is shown in SEQ ID NO: 2. The term "receptor polynucleotide" or "receptor nucleic acid" further includes variants and fragments of 14400 polynucleotides.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13706398A | 1998-08-20 | 1998-08-20 | |
| US09/137,063 | 1998-08-20 | ||
| US37810099A | 1999-08-20 | 1999-08-20 | |
| US09/378,100 | 1999-08-20 | ||
| PCT/US1999/019112 WO2000011170A1 (en) | 1998-08-20 | 1999-08-20 | 14400 receptor, a g-protein coupled receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003532369A JP2003532369A (en) | 2003-11-05 |
| JP2003532369A5 true JP2003532369A5 (en) | 2006-10-05 |
Family
ID=26834887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000566424A Withdrawn JP2003532369A (en) | 1998-08-20 | 1999-08-20 | 14400 receptor which is a G protein-coupled receptor |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1104465A1 (en) |
| JP (1) | JP2003532369A (en) |
| AU (1) | AU5578699A (en) |
| CA (1) | CA2340457A1 (en) |
| WO (1) | WO2000011170A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2289610T3 (en) * | 1998-11-20 | 2008-02-01 | Arena Pharmaceuticals, Inc. | RECEPTOR COUPLED TO HUMAN ORGAN PROTEIN G RUP3. |
| US7816492B2 (en) | 1998-11-20 | 2010-10-19 | Arena Pharmaceuticals, Inc. | Human G protein-coupled receptors |
| US20030017528A1 (en) | 1998-11-20 | 2003-01-23 | Ruoping Chen | Human orphan G protein-coupled receptors |
| USRE42190E1 (en) | 1998-11-20 | 2011-03-01 | Arena Pharmaceuticals, Inc. | Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors |
| AU8188101A (en) * | 2000-06-26 | 2002-01-08 | Bayer Ag | Regulation of human p2y8-like g protein-coupled receptor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69632830T2 (en) * | 1995-11-21 | 2005-08-25 | Euroscreen S.A. | RECEPTOR AND NUCLEIC ACID MOLECULAR CODING THEREFOR |
-
1999
- 1999-08-20 JP JP2000566424A patent/JP2003532369A/en not_active Withdrawn
- 1999-08-20 CA CA002340457A patent/CA2340457A1/en not_active Abandoned
- 1999-08-20 WO PCT/US1999/019112 patent/WO2000011170A1/en not_active Application Discontinuation
- 1999-08-20 EP EP99942397A patent/EP1104465A1/en not_active Ceased
- 1999-08-20 AU AU55786/99A patent/AU5578699A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003501038A5 (en) | ||
| CA2247285A1 (en) | Human tumor necrosis factor delta and epsilon | |
| AU2014373927B2 (en) | Prostate cancer gene profiles and methods of using the same | |
| KR20080042162A (en) | Composition and method for diagnosing kidney cancer and estimating kidney cancer patient's prognosis | |
| WO1999033963A1 (en) | Metastatic cancer regulated gene | |
| CA2273821A1 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
| DE60041265D1 (en) | USE OF A POLYPEPTIDE FOR MAKING MULTIPLE SCLEROSIS | |
| CA2269634A1 (en) | Reagents and methods useful for detecting diseases of the breast | |
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| JP2003524387A5 (en) | ||
| CA2302808A1 (en) | 50 human secreted proteins | |
| JP2004500013A5 (en) | ||
| CA2343979A1 (en) | Human interleukin-b50, therapeutic uses | |
| WO2000023588B1 (en) | G-protein coupled receptors | |
| JP2005520498A5 (en) | ||
| CA2294472A1 (en) | Torsin, torsin genes, and methods of use | |
| CA2287571A1 (en) | Reagents and methods useful for detecting diseases of the prostate | |
| JP2005507648A5 (en) | ||
| JP2003532369A5 (en) | ||
| JP4629873B2 (en) | Monocyte-derived nucleic acids and related compositions and methods | |
| US6544742B1 (en) | Detection of genes regulated by EGF in breast cancer | |
| CA2554440A1 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer | |
| CA2408847A1 (en) | Cng3b: a novel cyclic nucleotide-gated cation channel | |
| CA2418848A1 (en) | Cng2b: a novel human cyclic nucleotide-gated ion channel | |
| CA2374377A1 (en) | Potassium channel kcnq5 |